Abstract: Compounds of the formula ##STR1## in which Y is ##STR2## X is O or S; Z is --CHOH--CH.sub.2 --CHOH--CH.sub.2 --COOH, an ester or salt thereof or the lactone thereof; andeach of R.sup.1, R.sup.2 and R.sup.3 can be alkyl, cycloalkyl; or substituted or unsubstituted phenyl; and additionally R.sup.3 can be hydrogen, are obtained by a multi-step process and are useful in the treatment of atherosclerosis, e.g. sodium(E)-7-(4-phenyl-2-isopropyl-5-phenylthien-3-yl)-3,5-dihydroxyhept-6- enoate.

Abstract: This invention relates to chiral compositions.

Abstract: Compounds of the formula ##STR1## and processes for and intermediates in the synthesis thereof, pharmaceutical compositions comprising such a compound and the use of such compounds for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis.

Abstract: The invention discloses certain N-alkyl-(2- or 5-substituted-2-methoxycarbonyl aminoalkyl furanyl)-substituted cyclimmonium salts useful as PAF inhibitors, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for inhibiting PAF-induced blood platelet aggregation, PAF-mediated bronchoconstriction and extravasation, PAF-induced hypotension, PAF-induced ischemic bowel disease and PAF-mediated, endotoxin-induced lung injury.

Abstract: Compounds of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof, wherein the various substituents are defined hereinbelow and the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is C.sub.1-3 alkyl, andZ is ##STR2## wherein R.sub.7 is hydrogen, R.sub.8 or M,whereinR.sub.8 is a physiologically acceptable and hydrolyzable ester group, andM is a pharmaceutically acceptable cation,the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

Abstract: A therapeutic composition comprising a therapeutic macromolecular agent incorporated in cross-linked polyacetal.

Abstract: Compounds of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof, wherein the various substituents are defined herein below,the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

Abstract: 7-(indolizin-2-yl)hept-6-enoic acids of the formula I: ##STR1## wherein each of R.sup.1 and R.sup.2 is, independently, H, alkyl, cycloalkyl, aralkyl or aryl, ##STR2## in which R.sup.8 is H, an ester residue or cation; or the lactone thereof. The compounds are useful as hypocholesteremic agents.

Abstract: The invention discloses hydroxy-[1-substituted carbonyl-2-(or 3-) piperidinyl methoxy]phosphinyloxy]-N,N,N-trilkylalkaneaminium hydroxide inner salt oxides useful as antitumor agents, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for treating tumors.

Abstract: Thiazoles or pharmaceutically acceptable acid addition salts thereof are useful as anxiolytic, psychogeriatric, antidepressant and antischizophrenic agents.

Abstract: Virus insecticide compositions having good stability and wettability are free-flowing particles prepared by spray-drying techniques and having the virus insecticide encapsulated in a matrix comprising an intimate mixture of a protein and clay.

Abstract: Amines are substituted, e.g. alkylated, by reacting the unsubstituted amine with a ketone or aldehyde, a borohydride and a rigid acid.

Abstract: Compounds of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof, wherein the various substituents are defined hereinbelow, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

Abstract: 6-trans-indol-2-yl-ethenyl)-4-hydroxy-tetrahydro-2H-pyran-2-ones of formula I are obtained by a multi-step reaction involving the procedure: ##STR1## wherein p.sup.1 is trisubstituted silyl protective group, and Z is a 2-indolyl radical which may be bear at the 4, 5, 6 and 7-positions up to two substituents such as alkyl, alkoxy, halo and CF.sub.3, and at either one the 1 or 3-positions a substituted or unsubstituted phenyl; and at the other an assymetric alkyl, cycloalkyl or aralkyl radical. Compounds I, e.g. (E)-trans-6-[1'-methyl-3'-(4"-fluorophenyl)indol-2'-ylethenyl]3,4,5,6 -tetrahydro-4-hydroxy-2H-pyran-2-one(4R,6S); are useful as anti-atheroselerotic agents.

Abstract: The invention discloses certain substituted 2-furanyl- or 5-oxo-2-furanyl methoxy phosphoryl alkyl cyclimmonium salts useful as PAF inhibitors, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for inhibiting PAF-induced blood platelet aggregation, PAF-mediated bronchoconstriction and extravasation, PAF-induced hypotension and PAF-induced ischemic bowel disease.